CMND Clearmind Medicine Inc.
USHealthcareAs of 2026-07-10 16:00
Why CMND matters now
Clearmind Medicine Inc. (CMND) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.03 with -1.93% on the session and $2.1M in market capitalization; recent performance reads 1-month +30.08% and YTD -83.04%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.9M, and EPS of $-3.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -229.3%.
The latest indexable market news headline is "Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative" from Globe News Wire.
Additional event context on this page matters because recent insider activity includes HRT FINANCIAL LP filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.08
P/S
0.00
EV/EBITDA
1.12
DCF Value
$1.01
FCF Yield
-229.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-138.2%
ROA
-54.4%
ROIC
-69.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.9M | $-3.32 |
| Q4 2025 | $0.00 | $-687.8K | $-0.48 |
| FY 2025 | $0.00 | $-3.9M | $-3.03 |
| Q3 2025 | $0.00 | $-1.3M | $-0.98 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
-1.24
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.